查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1474906

mRNA 藥物市場規模、佔有率、趨勢分析報告：按應用、類型、最終用途、地區、細分市場預測，2024-2030 年

mRNA Therapeutics Market Size, Share & Trends Analysis Report By Application (Rare Genetic Diseases, Oncology, Respiratory Diseases, Infectious Diseases), By Type (Prophylactic, Therapeutic), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

mRNA藥物市場的成長與趨勢：

Grand View Research的最新報告顯示，到2030年，全球mRNA藥物市場預計將達到313億美元。

預計2024年至2030年複合年成長率為17.05%。推動市場成長的主要因素之一是糖尿病、愛滋病毒、癌症和心血管疾病等慢性病和感染疾病的盛行率不斷上升。對抗伊波拉出血熱、流感、愛滋病毒和最近的 COVID-19 等病毒性疾病的治療和疫苗接種需求不斷成長，預計將推動產業成長。 COVID-19病毒引起了許多政府機構和疫苗製造商的關注，這有望加速市場擴張。

此外，多家供應商正在使用新技術，例如將第一階段和第二階段臨床試驗階段結合起來，並更快地獲得衛生當局的監管批准，以預測在此期間全球疫苗接種劑量的可用性，預計將有助於疫苗接種量的成長行業。與傳統藥物相比，透過使用最尖端科技，可以生產出 mRNA 疫苗和治療藥物。這些產品的製造成本較低，抗感染疾病能力更強，並且具有增強的免疫抗原性。用於 mRNA 體內系統遞送的脂質奈米顆粒成分的進步也為市場擴張創造了良好的前景。

例如，2022 年 3 月，美國國立衛生研究院下屬國家過敏和感染疾病研究所 (NIAID) 報告稱，我們已開始一項評估三種潛在 HIV 疫苗的 1 期臨床試驗。因此，需求將會增加，進一步支撐產業的成長。

作為另一個重要的成長動力，製藥公司正在投資 mRNA 技術。預計該市場也將受到生物技術相關研發（R&D）措施和醫療技術進步等其他因素的推動。例如，Moderna 和阿斯特捷利康正在合作使用 mRNA 治療心肌缺血（一種心臟疾病，當流向心臟的血流減少，導致心肌缺氧時發生）。同樣，Arcturus Therapeutics 正在測試針對心臟病的 mRNA 療法。此類投資可能會補充未來幾年的市場成長。

COVID-19 大流行預計將對行業成長產生積極影響。 COVID-19 疫苗是一種使用 mRNA 技術治療的疾病。 COVID-19疫苗主要用於癌症治療，是推動mRNA市場的主要因素。由於冠狀病毒突變和病毒變種傳播的可能性，mRNA 公司正在努力開發下一代 COVID-19 疫苗。例如，2022 年 6 月，食品藥物管理局核准Moderna COVID-19 疫苗和輝瑞 &BioNTech COVID-19 疫苗用於 6 個月大的兒童，作為預防 COVID-19 的措施。因此，在 COVID-19 大流行期間，這些技術的使用預計會增加，從而帶動產業成長。

此外，近年來出現了明顯的整合趨勢，參與者結成策略聯盟以支持當前的研發計劃。例如，2021 年 2 月，葛蘭素史克 (GlaxoSmithKline plc) 和 CureVac NV 宣布達成一項價值 1.5236 億美元的新協議，以在當前合作夥伴關係的基礎上開發下一代 COVID-19 mRNA 疫苗。隨著領先的基於 mRNA 的療法/疫苗通過臨床試驗展示概念驗證、進展並最終推向市場，在可預見的未來，這一專業行業領域的利益相關人員的機會將繼續成長，預計將顯著增加。

mRNA 製藥市場報告亮點

  • 按應用，市場進一步細分為罕見遺傳疾病、腫瘤、呼吸系統疾病、感染疾病等。
  • 按類型分類，市場進一步細分為預防和治療。至2023年，預防領域將完全主導市場，佔有率達100%。
  • 根據最終用途，市場進一步細分為醫院/診所、研究機構等。預計到2023年，醫院和診所領域將佔據市場主導地位，佔有率為45.36%，並在2024年至2030年期間成長最快。
  • 北美mRNA藥物收益佔有率最大，2023年市佔率為40.37%。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第 4 章應用程式的商業分析

  • 使用細分儀表板
  • mRNA醫藥市場：應用變化分析
  • 2018-2030 年 mRNA 藥物市場規模與趨勢分析（按應用）
  • 罕見遺傳疾病
  • 瘤
  • 呼吸系統疾病
  • 感染疾病
  • 其他

第5章業務分析的類型

  • 類型細分儀表板
  • mRNA藥物市場：類型變異分析
  • 2018-2030 年 mRNA 藥物市場規模及趨勢分析（按類型）
  • 預防
  • 治療

第 6 章最終用途業務分析

  • 最終用途細分儀表板
  • mRNA 藥物市場：最終用途變異分析
  • 2018-2030 年 mRNA 藥物市場規模與趨勢分析（依最終用途）
  • 醫院/診所
  • 研究機構
  • 其他

第7章 區域業務分析

  • 區域儀表板
  • 2023 年和 2030 年市場規模和預測/趨勢分析
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 公司分類
  • 策略規劃
  • 2023 年企業市場分析
  • 公司簡介/上市公司
    • Moderna Inc.
    • BioNTech SE
    • CureVac NV
    • Arcturus Therapeutics
    • Sanofi
    • GSK plc.
    • Argos Therapeutics Inc.
    • Ethris
    • Pfizer Inc.
    • AstraZeneca
Product Code: GVR-4-68039-957-3

mRNA Therapeutics Market Growth & Trends:

The global mRNA therapeutics market size is expected to reach USD 31.30 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 17.05% from 2024 to 2030. One of the main factors propelling the market growth is the rising incidence of chronic and infectious diseases like diabetes, HIV, cancer, and CVDs. The growing need for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and most recently COVID-19 is expected to fuel industry growth. The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.

Furthermore, the availability of vaccination doses around the world is projected to increase during the forecast period as a result of multiple suppliers using novel techniques, such as combining the phase 1 and phase 2 clinical trial stages and obtaining regulatory clearances more quickly from health agencies, thus contributing to the industry growth. With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications. These products are less expensive to produce, more powerful against infections, and have enhanced immunogenicity. A favorable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.

For instance, in March 2022, The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) launched a phase 1 clinical trial to assess three potential HIV vaccines using a messenger RNA (mRNA) platform due to its active component and direct the cells to make a protein (or perhaps a protein fragment) that stimulates an immune response using artificial mRNA created in a lab, which enhances the vaccine with more specificity as well as robust stability. Thus, it will increase the demand and further boost the industry growth.

As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug. The market is expected to be driven by additional factors, such as significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology. For instance, Moderna and AstraZeneca are working together on a myocardial ischemia therapy using mRNA (a form of cardiac disease that develops when there is a decrease in blood flow to the heart, depriving the heart muscle of necessary oxygen). Similarly, mRNA treatments for heart disease are also being tested by Arcturus Therapeutics. Such investments are likely to supplement the market growth in the coming years.

The COVID-19 pandemic is anticipated to positively impact the industry growth. The COVID-19 vaccine is one of the diseases for which the mRNA technology is being used. In addition to its predominant use in cancer therapy, the COVID-19 vaccine is the main factor driving the market for mRNA. The mRNA firms are working hard to create COVID-19 vaccines for the next generation due to the coronavirus mutation and the potential spread of virus variants. For instance, in June 2022, The Food and Drug Administration approved the Moderna COVID-19 Vaccine and also the Pfizer & BioNTech COVID-19 Vaccine for use in children as young as 6 months old as COVID-19 preventative measures. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic and result in industry growth.

Additionally, there has been a discernible trend toward consolidation over the past few years, with players forming strategic alliances to support current R&D projects. For instance, in February 2021, building on their current partnership, GlaxoSmithKline plc and CureVac N.V. announced a new USD152.36 million agreement to create COVID-19 next-generation mRNA vaccines with the possibility for a multi-valent strategy to address numerous developing variations in a single vaccination. As additional mRNA-based therapeutic / vaccine leads exhibit proof-of-concept, go through clinical testing, and eventually hit the market, the opportunity for stakeholders involved in this specialized industry segment is likely to experience a significant increase in the predicted future.

mRNA Therapeutics Market Report Highlights:

  • Based on applications, the market is further segmented into rare genetic diseases, oncology, respiratory diseases, infectious diseases, and others.
  • Based on types, the market is further categorized into prophylactic and therapeutic. The prophylactic segment completely dominated the market with a share of 100% in 2023.
  • Based on end-uses, the market is further segmented into hospitals & clinics, research organizations, and others. The hospitals & clinics segment dominated the market with a share of 45.36% in 2023 and is expected to register the fastest growth rate from 2024 to 2030
  • The North America mRNA therapeutics market accounted for the largest revenue share of 40.37% share in 2023

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Application Segment
    • 1.1.2. Type Segment
    • 1.1.3. End-use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Primary Research
  • 1.6. Information or Data Analysis:
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations
  • 1.11. Objective

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Academic and industrial interest in mRNA
      • 3.2.1.3. Advantages of mRNA vaccines
      • 3.2.1.4. Growing demand for therapeutic medicines
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Stringent government regulations for mRNA-based product approvals
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Application Business Analysis

  • 4.1. Application Segment Dashboard
  • 4.2. mRNA Therapeutics Market Application Movement Analysis
  • 4.3. mRNA Therapeutics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Rare Genetic Diseases
    • 4.4.1. Rare genetic diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Oncology
    • 4.5.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Respiratory Diseases
    • 4.6.1. Respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.7. Infectious Diseases
    • 4.7.1. Infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. mRNA Therapeutics Market Type Movement Analysis
  • 5.3. mRNA Therapeutics Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Prophylactic
    • 5.4.1. Prophylactic market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Therapeutic
    • 5.5.1. Therapeutic market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. End-use Segment Dashboard
  • 6.2. mRNA Therapeutics Market End-use Movement Analysis
  • 6.3. mRNA Therapeutics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals & Clinics
    • 6.4.1. Hospitals & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Research Organizations
    • 6.5.1. Research organizations market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis by Application, Type, End-use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecast and Trend Analysis, 2023 & 2030
  • 7.3. North America
    • 7.3.1. North America mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Market Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Disease Prevalence
      • 7.3.2.6. Reimbursement Scenario
      • 7.3.2.7. U.S. mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Market Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Disease Prevalence
      • 7.3.3.6. Reimbursement Scenario
      • 7.3.3.7. Canada mRNA Therapeutics Market, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Market Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Disease Prevalence
      • 7.4.2.6. Reimbursement Scenario
      • 7.4.2.7. UK mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Market Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Disease Prevalence
      • 7.4.3.6. Reimbursement Scenario
      • 7.4.3.7. Germany mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Market Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Disease Prevalence
      • 7.4.4.6. Reimbursement Scenario
      • 7.4.4.7. France mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Market Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Disease Prevalence
      • 7.4.5.6. Reimbursement Scenario
      • 7.4.5.7. Italy mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Market Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Disease Prevalence
      • 7.4.6.6. Reimbursement Scenario
      • 7.4.6.7. Spain mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Disease Prevalence
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Denmark mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Market Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Disease Prevalence
      • 7.4.8.5. Reimbursement Scenario
      • 7.4.8.6. Sweden mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Disease Prevalence
      • 7.4.9.5. Reimbursement Scenario
      • 7.4.9.6. Norway mRNA Therapeutics Market, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Japan mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. China mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. India mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Scenario
      • 7.5.5.5. Australia mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Scenario
      • 7.5.6.5. Thailand mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Scenario
      • 7.5.7.5. South Korea mRNA Therapeutics Market, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Brazil mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.6.3. Mexico
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Mexico mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.6.4. Argentina
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Argentina mRNA Therapeutics Market, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Market Scenario
      • 7.7.2.4. Regulatory Framework
      • 7.7.2.5. Disease Prevalence
      • 7.7.2.6. Reimbursement Scenario
      • 7.7.2.7. South Africa mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Scenario
      • 7.7.3.5. Saudi Arabia mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. Reimbursement Scenario
      • 7.7.4.5. UAE mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Reimbursement Scenario
      • 7.7.5.5. Kuwait mRNA Therapeutics Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Moderna Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. BioNTech SE
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. CureVac N.V.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Arcturus Therapeutics
      • 8.4.4.1. Overview
      • 8.4.4.2. Product Benchmarking
      • 8.4.4.3. Strategic Initiatives
    • 8.4.5. Sanofi
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. GSK plc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Argos Therapeutics Inc.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Ethris
      • 8.4.8.1. Overview
      • 8.4.8.2. Product Benchmarking
      • 8.4.8.3. Strategic Initiatives
    • 8.4.9. Pfizer Inc.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. AstraZeneca
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global mRNA therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America mRNA therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 4 North America mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 U.S. mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 12 Canada mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 13 Europe mRNA therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 14 Europe mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 15 Europe mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 16 Europe mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 Germany mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 18 Germany mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 19 Germany mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 UK mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 21 UK mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 22 UK mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 France mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 24 France mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 25 France mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Italy mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 27 Italy mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 28 Italy mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Spain mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 30 Spain mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 31 Spain mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Denmark mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 33 Denmark mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 34 Denmark mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 Sweden mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 36 Sweden mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 37 Sweden mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 38 Norway mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 39 Norway mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 40 Norway mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific mRNA therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 45 China mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 46 China mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 47 China mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Japan mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 49 Japan mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 50 Japan mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 51 India mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 52 India mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 53 India mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 South Korea mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 55 South Korea mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 56 South Korea mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 Australia mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 58 Australia mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 59 Australia mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 60 Thailand mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 61 Thailand mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 62 Thailand mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 63 Latin America mRNA therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 64 Latin America mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 65 Latin America mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 66 Latin America mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 67 Brazil mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 68 Brazil mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 69 Brazil mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 70 Mexico mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 71 Mexico mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 72 Mexico mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 73 Argentina mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 74 Argentina mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 75 Argentina mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 76 MEA mRNA therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 77 MEA mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 78 MEA mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 79 MEA mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 80 South Africa mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 81 South Africa mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 82 South Africa mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 86 UAE mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 87 UAE mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 88 UAE mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 89 Kuwait mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 91 Kuwait mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 mRNA therapeutics market: market outlook
  • Fig. 7 mRNA therapeutics competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 mRNA therapeutics market driver impact
  • Fig. 11 mRNA therapeutics market restraint impact
  • Fig. 12 mRNA therapeutics market strategic initiatives analysis
  • Fig. 13 mRNA therapeutics market: type movement analysis
  • Fig. 14 mRNA therapeutics market: type outlook and key takeaways
  • Fig. 15 Prophylactic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Therapeutic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 mRNA therapeutics market: application movement analysis
  • Fig. 18 mRNA therapeutics market: application outlook and key takeaways
  • Fig. 19 Infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Rare genetic diseases market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 22 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 mRNA therapeutics market: end-use movement analysis
  • Fig. 25 mRNA therapeutics market: end-use outlook and key takeaways
  • Fig. 26 Hospitals & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Research organizations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 North America mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Canada mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Europe mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 UK mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Germany mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 France mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Italy mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Spain mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Denmark mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sweden mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Norway mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Asia Pacific mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 China mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 India mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Latin America mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Brazil mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Mexico mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Middle East and Africa mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 UAE mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Market positioning of key market players- mRNA therapeutics market